Acute Myeloid Leukemia With FLT3/ITD Mutation Clinical Trials

15 clinical trials for Acute Myeloid Leukemia With FLT3/ITD Mutation across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation — RECRUITING · PHASE1
• Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML — RECRUITING · PHASE1
• A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants — RECRUITING · PHASE1
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies — COMPLETED · PHASE2
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer — TERMINATED · PHASE2
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia — COMPLETED · PHASE1
• A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) — NOT_YET_RECRUITING · PHASE3
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — TERMINATED · PHASE2
• The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT — OTHER
• The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT — OTHER
• Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia — COMPLETED · PHASE2
• Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML — COMPLETED
• AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance — OTHER · PHASE3
• Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation — TERMINATED · PHASE2

Refine this search